Komori
Earnings4552JCR Pharmaceuticals Co.,Ltd.Pharmaceuticals

(Correction) Partial correction to the "Summary of Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2026 (Japanese GAAP) (Consolidated)"

A portion of the FY2026 second-quarter (interim) financial results summary announced on 30 October 2025 was corrected. The specific items or figures corrected cannot be determined from the provided text.

Worth reading
100Important
Scored from 1 of 3 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Avoiding a definitive answer
How definitive the wording is.

What was corrected and how

A subsequent correction by the company to the contents of an already published filing.

Original disclosure30 October 2025

FY2026 Second-Quarter (Interim) Financial Results Summary [Japanese GAAP] (Consolidated)

Open the original document
195 daysThe pre-correction wording stayed published for this period (Calculated from the Original Disclosure Date Indicated in the Document)
This correction2026-05-13
Reason for correction

Because the "FY2026 Second-Quarter (Interim) Financial Results Summary [Japanese GAAP] (Consolidated)" contained some errors.

What was corrected and how
ItemDetails
Disclosure subject to correctionFY2026 Second-Quarter (Interim) Financial Results Summary [Japanese GAAP] (Consolidated)
Original disclosure date30 October 2025
Reason for correctionBecause the "FY2026 Second-Quarter (Interim) Financial Results Summary [Japanese GAAP] (Consolidated)" contained some errors.
Items this document does not state (3)
Location of correctionDetails of correctionImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Because the relevant financial results summary contained some errors.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
(Correction) Partial correction to the "Summary of Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2026 (Japanese GAAP) (Consolidated)" | JCR Pharmaceuticals Co.,Ltd. (4552) timely disclosure | Komori